Operation Warp Speed

ISPE Pharmaceutical Engineering® "Special Report: COVID-19" Honored with 2023 APEX Award

Retrieved on: 
Monday, August 21, 2023
Vaccine, NORTH, Therapy, ISPE, Operation Warp Speed, Consultant, Writing, COVID-19, Medication, CQA, Technical Service Council, Toxicology, Research, DABT, Doctor of Philosophy, The View from the Inside, Organization, Grand Award Records, International Society, Pharmaceutical industry

NORTH BETHESDA, Md., Aug. 21st, 2023 /PRNewswire-PRWeb/ -- The International Society for Pharmaceutical Engineering (ISPE) has been honored with a 2023 APEX Grand Award for Public Health Concerns for their "Special Report: COVID-19." This included two articles, "Pandemic Progress: Industry's Journey from 2020 to Today" and "Operation Warp Speed: A View From the Inside." Both articles were published in the May/June 2022 issue of Pharmaceutical Engineering®. This marks the fourth consecutive year that Pharmaceutical Engineering® has received an APEX Award.

Key Points: 
  • The International Society for Pharmaceutical Engineering (ISPE) has been honored with a 2023 APEX Grand Award for Public Health Concerns for their "Special Report: COVID-19."
  • This included two articles, "Pandemic Progress: Industry's Journey from 2020 to Today" and "Operation Warp Speed: A View From the Inside."
  • NORTH BETHESDA, Md., Aug. 21st, 2023 /PRNewswire-PRWeb/ -- The International Society for Pharmaceutical Engineering (ISPE) has been honored with a 2023 APEX Grand Award for Public Health Concerns for their "Special Report: COVID-19."
  • This marks the fourth consecutive year that Pharmaceutical Engineering® has received an APEX Award.

Bluestone Investment Partners Announces Board of Advisors

Retrieved on: 
Tuesday, July 25, 2023
Communication, Public sector, Army, United States Department of Defense, Ernst & Young, Special, Perna, Acquisition, Air force, SVP, White House, Deputy Chief of Staff for Intelligence, Surveillance, Reconnaissance, and Cyber Effects Operations of the United States Air Force, Public, LMI, ISR, CACI, AMC, US Airways, Mass, Growth, Weapon, Private sector, United States Air Force, USAF, Operation Warp Speed, V&A Digital Futures, Talent management, Central Waqf Council, Government, CIA, Directorate, CFO, Army Materiel Command, Salesforce, Australian Intelligence Community, SVP-24, Federation, IC, Sale, Public Interest Declassification Board, RET, Unitary state, Iron, Management, Intelligence, Headquarters, Bluestone

MCLEAN, Va., July 25, 2023 /PRNewswire/ -- Bluestone Investment Partners, LP ("Bluestone"), a McLean, Virginia-based private equity firm focused on investing in defense, intelligence, and federal technology solutions providers, announced today the formation of its Board of Advisors, which includes five renowned industry leaders.

Key Points: 
  • MCLEAN, Va., July 25, 2023 /PRNewswire/ -- Bluestone Investment Partners, LP ("Bluestone"), a McLean, Virginia-based private equity firm focused on investing in defense, intelligence, and federal technology solutions providers, announced today the formation of its Board of Advisors, which includes five renowned industry leaders.
  • The Board will provide strategic guidance and subject matter expertise to Bluestone and its portfolio companies.
  • Our Board of Advisors fits this description perfectly.
  • We look forward to their engagement with Bluestone and our portfolio companies," said John Allen, Managing Partner of Bluestone.

DPHARM's 13th Annual Event on Modernizing Clinical Research Announces the 2023 Agenda from the Conference Forum

Retrieved on: 
Monday, July 17, 2023
Learning, Senior, Operation Warp Speed, Culture, Biogen, Clinical trial, Copley Place, SVP, Conference, Pharmaceutical industry

NEW YORK, July 17, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced today the launch of the 13th annual DPHARM: Disruptive Innovations to Modernize Clinical Research conference, taking place September 20-22, 2023 in Boston at the Westin Copley Place.

Key Points: 
  • The Conference Forum announced the launch of the 13th annual DPHARM: Disruptive Innovations to Modernize Clinical Research with the focus on sustaining a culture of efficiencies that can drive innovation.
  • NEW YORK, July 17, 2023 /PRNewswire-PRWeb/ -- The Conference Forum announced today the launch of the 13th annual DPHARM: Disruptive Innovations to Modernize Clinical Research conference, taking place September 20-22, 2023 in Boston at the Westin Copley Place.
  • "DPHARM is the most highly anticipated event of the year for the clinical trials community because it reports on innovation to increase trial access, reduce burden to patient participation, increase efficiencies and reduce time to market," said Valerie Bowling, Executive Director, Conference Forum.
  • "DPHARM also brings the perspective of the patient and from outside the industry, which differentiates it from other conferences."

Adeno Associated Virus Vector Manufacturing Global Market Report 2023: Robust Pipelines for Gene Therapies and Vaccines Bolsters Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 5, 2023
Biotechnology, Pharmaceutical, Health, Vaccine, Dyno, Duchenne muscular dystrophy, Therapy, Astellas Pharma, Prevalence, CGMP, NGS, COVID-19, Retinitis pigmentosa, Cancer, Research, Antibody, AAV, USD, Government, Incidence, UCB, Genetic disorder, Investment, Application, Cystic fibrosis, Growth, Operation Warp Speed, Commercial, Gene, Family, Pharmaceutical industry

The "Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations (Clinical, Commercial), By Method, By Application, By Therapeutic Area, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations (Clinical, Commercial), By Method, By Application, By Therapeutic Area, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global adeno associated virus vector manufacturing market size is expected to reach USD 3.95 billion by 2030, registering a CAGR of 22.5% over the forecast period.
  • As adeno associated virus has vast applications in vaccine manufacturing, various companies were involved in the race to manufacture the vaccine to treat COVID-19.
  • Adeno Associated Virus Vector Manufacturing Market: Scale Of Operations Movement Analysis

EverGlade Consulting Funding Alert: Biden Administration Announces Launch of Successor Program to Operation Warp Speed Accompanied by the Release of New Funding Opportunities for the Development of Vaccines and Therapeutics

Retrieved on: 
Wednesday, April 12, 2023
MSD, EUA, Vaccine, Injection, ASPR, Private sector, Drug Master File, Biomedical Advanced Research and Development Authority, White, Interest, Half-life, Operation Warp Speed, SARS-CoV-2, Pediatrics, Hook effect, Coronavirus, COVID-19, Trump, RFI, Multimedia, Pre-exposure prophylaxis, AOI, MERS-related coronavirus, DTRA, Trial of the century, Project, Implementation, Development, DARPA, JPM, COVID-19 vaccine, Documentation, Emerging Infectious Diseases (journal), Area, Investigational New Drug, CGMP, Collection, Treatment, SARS-CoV-1, Toxicology, DMF, Federation, Immunodeficiency, API, FDA, Therapy, BARDA, NIH, IND, ACE2, Safety, Pharmaceutical industry, Chemical substance

The assays should analyze clinical study samples and measure immune responses to both ancestral SARS-CoV-2 and variants of concern.

Key Points: 
  • The assays should analyze clinical study samples and measure immune responses to both ancestral SARS-CoV-2 and variants of concern.
  • Assays of interest include lentivirus-based virus neutralization assays, multiplexed antigen panels, and MSD-based ACE2 receptor blocking assays.
  • "Given the success of Project Warp Speed, it is no surprise that BARDA would try to build on that success," stated EverGlade Consulting Founder, Eric Jia-Sobota.
  • For additional information about EverGlade Consulting, visit:
    View original content to download multimedia: https://www.prnewswire.com/news-releases/everglade-consulting-funding-al...

ResultsCX Adds McKinsey Alum Paul Mango to Board of Directors

Retrieved on: 
Wednesday, March 29, 2023
Private sector, Paul, U.S. Department of Defense Strategy for Operating in Cyberspace, Centers for Medicare & Medicaid Services, Pacific Equity Partners, Operation Warp Speed, Human services, Office of Inspector General, U.S. Department of Health and Human Services, COVID-19, History, McKinsey & Company, Government, Medicare, Partnership, CIO, Center for Medicare and Medicaid Innovation, Management

FORT LAUDERDALE, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- ResultsCX, a premier customer experience partner to Fortune-100 and 500 companies, today announced the appointment of Paul Mango as a new member of its Board of Directors.

Key Points: 
  • FORT LAUDERDALE, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- ResultsCX, a premier customer experience partner to Fortune-100 and 500 companies, today announced the appointment of Paul Mango as a new member of its Board of Directors.
  • Paul was Deputy Chief of Staff for the U.S. Department of Health and Human Services from 2019-2021, during which he was instrumental in advancing policies regarding consumer empowerment in the health care sector.
  • Paul has a stellar reputation, both from his time in government and throughout his impressive consulting tenure.
  • His experience with successful transformation will be crucial across every industry ResultsCX serves.”
    Paul Mango commented, “I am excited to join the ResultsCX Board and am impressed by the company’s commitment to excellence in serving every client’s customers.

Alex Azar Joins AbsoluteCare's Board of Directors

Retrieved on: 
Friday, January 6, 2023
Government, Medicaid, Eli Lilly and Company, Office of Inspector General, U.S. Department of Health and Human Services, United States Department of Health and Human Services, Economics, Healthcare Leadership Council, Operation Warp Speed, COVID-19, COVID-19 vaccine, HHS, University, Therapy, Human services, Quality of life, Senior, Medicare, Yale Law School, Health insurance, Pharmaceutical industry, Management, Health

COLUMBIA, Md., Jan. 6, 2023 /PRNewswire/ -- AbsoluteCare, a concierge, PCP-driven care model serving the most medically complex and compromised members, is pleased to welcome the 24th U.S. Secretary of Health and Human Services (HHS), Alex Azar, to our board.

Key Points: 
  • Most notably, his COVID-19 actions included Operation Warp Speed, which dramatically accelerated the creation and distribution of COVID-19 vaccines and therapeutics.
  • Secretary Azar is a natural fit, with the expertise to help AbsoluteCare expand efforts and prioritize specific healthcare initiatives.
  • "So much of the healthcare system rewards transactional services, encouraging treatments that are not correlated with improved outcomes," said Secretary Azar.
  • Secretary Azar is former president of the U.S. division of Eli Lilly and Company, a global pharmaceutical leader.

GI Alliance Announces Appointment of Two Industry Leaders to the Board of Managers

Retrieved on: 
Thursday, January 5, 2023
McKinsey & Company, Government, Office of Inspector General, U.S. Department of Health and Human Services, Business administration, United States Department of Health and Human Services, Division (military), Medicare Advantage, HMO, Physician, Operation Warp Speed, Department of Defence, Airborne forces, White House, Private sector, ACO, United States service academies, San Francisco State University, Master of Public Administration, Bachelor of Arts in Applied Psychology, Centers for Medicare & Medicaid Services, White, UnitedHealth Group, Harvard University, University, Master of Business Administration, 8th Infantry Division (Poland), Medi-Cal, Human services, California State University, East Bay, Army of the United States, PPO, Medicare, Medicaid, Management

DALLAS, Jan. 5, 2023 /PRNewswire/ -- GI Alliance, the nation's largest GI physician practice management company, today announced the appointment of Kelly Robison and Paul Mango to the GI Alliance Board of Managers ("Board"), effective November 29, 2022.

Key Points: 
  • DALLAS, Jan. 5, 2023 /PRNewswire/ -- GI Alliance, the nation's largest GI physician practice management company, today announced the appointment of Kelly Robison and Paul Mango to the GI Alliance Board of Managers ("Board"), effective November 29, 2022.
  • "We are excited to welcome Kelly Robison and Paul Mango to the GI Alliance Board," said James Weber, M.D., chairman and CEO of GI Alliance.
  • The new appointments to the Board will join the following board members: James Weber, M.D.
  • (GI Alliance CEO/Chairman), Jason Scheir (Apollo Hybrid Value Partner), Anton Finucane-Courreges (Apollo Global Management Principle), Paul Berggreen, M.D.

Global Biodefense Market Report to 2030 - Featuring Altimmune, Emergent BioSolutions, SIGA Technologies and Ichor Medical Systems Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, November 21, 2022
Biotechnology, Pharmaceutical, Health, Horizon, Prevalence, Incidence, European Commission, Operation Warp Speed, Plant, Zika virus, Public–private partnership, MCM, Merck, Bacteria, Office of Inspector General, U.S. Department of Health and Human Services, Framework Programmes for Research and Technological Development, Partnership, Infection, Bioterrorism, Government, Animal, National Healthcare Group, Korea Disease Control and Prevention Agency, CDC, Virus, Crimean–Congo hemorrhagic fever, Vaccination, Death, Human, USD, Military personnel, Research, Disease, Mortality, Fungus, Therapy, COVID-19 vaccine, Fever Dream, HHS, COVID-19, CCHF, Merck & Co., NHC, Vaccine, Pharmaceutical industry

The pandemic has also highlighted the importance of investing in strong biodefense infrastructure, which is expected to drive market growth over the forecast period.

Key Points: 
  • The pandemic has also highlighted the importance of investing in strong biodefense infrastructure, which is expected to drive market growth over the forecast period.
  • Biodefense comprises medical countermeasures (MCM) and other actions taken to protect people from the effects of biological warfare agents or bioterrorism.
  • The global biodefense market is expected to grow at a CAGR of over 12% during the period of 2021-2031.
  • For this report, the author has segmented the global biodefense market based on product type, application, end-use, and region:

ixlayer Announces Formation of Advisory Board

Retrieved on: 
Tuesday, November 1, 2022
Technology, Health Technology, Telemedicine, Virtual Medicine, Software, Practice Management, Other Health, General Health, Pharmaceutical, Health, Data Management, GSK, Retirement, Pharmacy, United States Coast Guard Auxiliary, COPE, Morristown Medical Center, COVID-19, Hospital, MHRI, Foundation, Kaiser Permanente, The Honourable, DTRA, Solution, GlaxoSmithKline, Clinton Foundation, Outreach, Operation Warp Speed, Board, Director, Head, Global Vaccines, Research, University, Veterans' affairs, Patient, Multimedia, University of Pennsylvania Health System, Senior, Movement, Drexel University School of Public Health, The Co Founder, Medical college, Editorial board, Time, Health, Decentralized Trials & Research Alliance, Therapeutic Innovation & Regulatory Science, Founder, Sarcoidosis, Pfizer, Salesforce, Health care, Hospital of the University of Pennsylvania, Innovation, Aetna, Government, Temple University Hospital, Pharmaceutical industry, Management, Medicine

ixlayer , the leading platform for health testing, announces today the formation of the ixlayer Health Testing Advisory Board .

Key Points: 
  • ixlayer , the leading platform for health testing, announces today the formation of the ixlayer Health Testing Advisory Board .
  • The ixlayer Health Testing Advisory Board will consist of industry leaders and experts who will serve as thought partners and strategists to further the movement of making health testing more accessible and affordable.
  • View the full release here: https://www.businesswire.com/news/home/20221101005418/en/
    ixlayer is appointing five members to its recently established ixlayer Heath Testing Advisory Board (iHTAB).
  • ixlayer is excited to take these next bold steps on our journey and welcomes these talented and respected professionals to our new advisory board, said Pouria Sanae , ixlayers Chief Executive Officer and co-founder.